Browse News

Found 36 articles

• Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis

  12/19/2022

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the European Commission (EC) and European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan designation for AT-01 (iodine (I-124) evuzamitide) as a diagnostic for the management of both immunoglobulin light chain amyloidosis (AL) and transthyretin (ATTR) amyloidosis.

• Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

  11/17/2022

  Attralus, Inc. and Ossianix announced today that they have entered into a definitive agreement using Ossianix' brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease.

• Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate

  10/17/2022

  Attralus, Inc. today announced that the first subject has been dosed in the Phase 1 clinical trial of AT-02, the company's lead pan-amyloid removal (PAR) therapeutic.

• Transthyretin Amyloidosis Treatment Market Research Report 2022-2030 | Share, Global Trends, Key Players, Growth Analysis to 2030

  10/6/2022

  Latest Study on “Transthyretin Amyloidosis Treatment Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

• New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

  10/4/2022

  The Amyloidosis Research Consortium announces the launch of ASPIRE: Amyloidosis Stakeholder Partnerships for Impact Reach and Equity, a collaborative of biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis and systems of care, and addressing obstacles to health equity on behalf of amyloidosis patients.

• Transthyretin Amyloidosis Treatment Market Size, Trends, Share, Growth | Report 2022-2030

  9/27/2022

  The global transthyretin amyloidosis treatment market size was estimated at around USD 4.87 billion in 2021 and it is projected to hit around USD 9.35 billion by 2030, growing at a CAGR of 7.52% from 2022 to 2030.

• Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis

  9/8/2022

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced multiple data presentations from the University of Tennessee Graduate School of Medicine for AT-01 (iodine (I-124) evuzamitide), the company’s pan-amyloid binding peptide in development as an amyloid-specific imaging agent for the diagnosis and management of all types of systemic amyloidosis.

• Attralus Announces New Preclinical Data Demonstrating Novel Human Chimeric Antigen Receptor-Macrophages (CAR-M) for Potential Amyloid Removal at 18th International Symposium on Amyloidosis

  9/6/2022

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced exciting new preclinical data from the University of Tennessee Graduate School of Medicine from its study on novel human chimeric antigen receptor-macrophages (CAR-M) as a potential therapeutic for amyloid clearance.

• Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

  8/22/2022

  Attralus, Inc. today announced that new data across the Company's amyloidosis portfolio will be presented in both oral and poster presentations at the XVIII International Symposium on Amyloidosis (ISA) by Attralus, the University of Tennessee Graduate School of Medicine and the Brigham and Women's Hospital.

• 

  FDA Review: Bayer, Daiichi Sankyo, AstraZeneca and More

  8/12/2022

  Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.

• Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis

  8/8/2022

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for 124 I-AT-01 (iodine (I-124) evuzamitide) as a diagnostic for the management of transthyretin amyloidosis (ATTR).

• Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

  6/14/2022

  Attralus, Inc today announced encouraging new clinical data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of AT-01 (Iodine I-124 evuzamitide), the company’s pan-amyloid binding peptide in development as a radiotracer for the diagnosis of multiple types of systemic amyloidosis.

• Attralus to Present New AT-01 Data at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

  6/3/2022

  Attralus, Inc., today announced that final data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of iodine evuzamitide (124I-AT-01), will be presented in both oral and poster presentations at the 2022 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting.

• Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session

  4/4/2022

  Attralus, Inc. announced encouraging new clinical data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of iodine evuzamitide, the company’s pan-amyloid binding peptide in development as a radiotracer for the diagnosis of systemic amyloidosis.

• BioTheryX Appoints Nancy Miller-Rich as Chair of Its Board of Directors

  2/23/2022

  BioTheryX, Inc. today announced that Nancy Miller-Rich has assumed the role of Chair of the BioTheryX Board of Directors.

• 

  BioSpace Movers & Shakers, Feb. 18

  2/18/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Movers & Shakers, Feb. 11

  2/11/2022

  Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

• Attralus Appoints James Testa as Vice President of Finance

  2/10/2022

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced the appointment of James Testa as Vice President of Finance.

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

• Attralus Presents Positive New Data at 2021 American Society of Hematology Annual Meeting

  12/13/2021

  Attralus, Inc. today announced encouraging new preclinical data for AT-03, the company’s first-in-class pan-amyloid removal (PAR) therapeutic being developed for the treatment of systemic amyloidosis.